Inhibition of cytochrome P450 3A by acetoxylated analogues of resveratrol in in vitro and in silico models

被引:14
|
作者
Basheer, Loai [1 ]
Schultz, Keren [1 ]
Kerem, Zohar [1 ]
机构
[1] Hebrew Univ Jerusalem, Robert H Smith Fac Agr Food & Environm, Inst Biochem Food Sci & Nutr, POB 12, IL-76100 Rehovot, Israel
来源
SCIENTIFIC REPORTS | 2016年 / 6卷
关键词
HERB-DRUG INTERACTION; P450-MEDIATED METABOLISM; STRUCTURAL BASIS; CYP3A4; RAT; MECHANISM; TRANSPORT; ENZYMES; LIVER; BIOAVAILABILITY;
D O I
10.1038/srep31557
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Many dietary compounds, including resveratrol, are potent inhibitors of CYP3A4. Here we examined the potential to predict inhibition capacity of dietary polyphenolics using an in silico and in vitro approaches and synthetic model compounds. Mono, di, and tri-acetoxy resveratrol were synthesized, a cell line of human intestine origin and microsomes from rat liver served to determine their in vitro inhibition of CYP3A4, and compared to that of resveratrol. Docking simulation served to predict the affinity of the synthetic model compounds to the enzyme. Modelling of the enzyme's binding site revealed three types of interaction: hydrophobic, electrostatic and H-bonding. The simulation revealed that each of the examined acetylations of resveratrol led to the loss of important interactions of all types. Triacetoxy resveratrol was the weakest inhibitor in vitro despite being the more lipophilic and having the highest affinity for the binding site. The simulation demonstrated exclusion of all interactions between tri-acetoxy resveratrol and the heme due to distal binding, highlighting the complexity of the CYP3A4 binding site, which may allow simultaneous accommodation of two molecules. Finally, the use of computational modelling may serve as a quick predictive tool to identify potential harmful interactions between dietary compounds and prescribed drugs.
引用
收藏
页数:13
相关论文
共 50 条
  • [41] In vivo approach for the evaluation of mechanism-based inhibition of cytochrome P450 3A in rats
    Sekiguchi, N.
    Kato, M.
    Takada, M.
    Watanabe, H.
    Higashida, A.
    Sakai, S.
    Ishigai, M.
    Aso, Y.
    XENOBIOTICA, 2008, 38 (04) : 368 - 381
  • [42] IN VIVO APPROACH FOR EVALUATION OF MECHANISM-BASED INHIBITION OF CYTOCHROME P450 3A IN RATS
    Sekiguchi, Nobuo
    Kato, Motohiro
    Takada, Maiko
    Watanabe, Hiroo
    Higashida, Atsuko
    Sakai, Shuichi
    Ishigai, Masaki
    Aso, Yoshinori
    DRUG METABOLISM REVIEWS, 2007, 39 : 317 - 318
  • [43] In silico cytochrome P450 and transporter modeling
    Korzekwa, KR
    DRUG METABOLISM REVIEWS, 2004, 36 : 21 - 21
  • [44] In silico prediction of cytochrome P450 inhibitors
    Refsgaard, Hanne H. F.
    Jensen, Berith F.
    Christensen, Inge Thoger
    Hagen, Nina
    Brockhoff, Per B.
    DRUG DEVELOPMENT RESEARCH, 2006, 67 (05) : 417 - 429
  • [45] Nonionic surfactants, are strong inhibitors of cytochrome P450 3A biotransformation activity in vitro and in vivo
    Ren, Xiuhua
    Mao, Xinliang
    Cao, Lei
    Xue, Kewen
    Si, Luqin
    Qiu, Jun
    Schimmer, Aaron D.
    Li, Gao
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2009, 36 (4-5) : 401 - 411
  • [46] Screening of cytochrome P450 3A4 inhibitors via in silico and in vitro approaches
    Pang, Xiaocong
    Zhang, Baoyue
    Mu, Guangyan
    Xia, Jie
    Xiang, Qian
    Zhao, Xia
    Liu, Ailin
    Du, Guanhua
    Cui, Yimin
    RSC ADVANCES, 2018, 8 (61) : 34783 - 34792
  • [47] Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism
    van Herwaarden, Antonius E.
    Wagenaar, Els
    van der Kruijssen, Cornelia M. M.
    van Waterschoot, Robert A. B.
    Smit, Johan W.
    Song, Ji-Ying
    van der Valk, Martin A.
    van Tellingen, Olaf
    van der Hoorn, Jose W. A.
    Rosing, Hilde
    Beijnen, Jos H.
    Schinkel, Alfred H.
    JOURNAL OF CLINICAL INVESTIGATION, 2007, 117 (11): : 3583 - 3592
  • [48] Genetic variability in cytochrome P450 3A5 and in vivo cytochrome P450 3A activity: Some answers but still questions
    Wilkinson, GR
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (02) : 99 - 103
  • [49] Mechanism-based inhibition of Alantolactone on human cytochrome P450 3A4 in vitro and activity of hepatic cytochrome P450 in mice
    Qin, Chong-Zhen
    Lv, Qiao-Li
    Wu, Na-Yiyuan
    Cheng, Lin
    Chu, Yun-Chen
    Chu, Tang-Yuan
    Hu, Lei
    Cheng, Yu
    Zhang, Xue
    Zhou, Hong-Hao
    JOURNAL OF ETHNOPHARMACOLOGY, 2015, 168 : 146 - 149
  • [50] Inhibition of cytochrome P450 by buckminsterfullerene
    Gannett, Peter
    Bostick, Christopher
    Tracy, Timothy
    Dolan, Emma
    Biundo, Andrew
    Tish, Wesley
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252